Gilead’s Bet in Cancer Treatment: A Valuation Shift Dependent on a Single FDA Ruling

Gilead Sciences: Market Optimism vs. Financial Fundamentals

Investors have been wagering on Gilead Sciences’ future prospects, driving its stock up by 23.3% since late 2025 and pushing shares close to a 52-week peak of $157.3. This surge reflects a classic case of “buying the rumor,” as enthusiasm for a new growth narrative has outpaced the company’s current financial performance. The heart of the matter is a significant disconnect between market expectations and Gilead’s actual results.

On one hand, investors are banking on a major transformation. The boldest move is Gilead’s $7.8 billion purchase of Arcellx at a 79% premium, signaling a strategic push into oncology—a field that’s new territory for Gilead. This acquisition, along with expansion in liver disease treatments and next-generation prevention, forms the crux of Wall Street’s renewed optimism. Reflecting this shift, there are 17 buy ratings and an average price target of $156.59 as of early March.

However, Gilead’s financials paint a less rosy picture. The stock’s rally comes despite sluggish revenue growth and falling returns on capital. Over the past five years, annual revenue has grown by just 3.6%, trailing industry peers, while earnings per share have increased by only 2.8% per year. The company’s core HIV business is maturing, and investors are being asked to look beyond current results to the promise of future product launches. The current valuation is a bet that new oncology and liver disease products will eventually compensate for the plateauing HIV segment, even though this shift isn’t yet visible in earnings.

Earnings: Surpassing Estimates but Facing Skepticism

Gilead’s latest fourth-quarter results highlighted the gap between expectations and reality. The company exceeded both revenue and earnings forecasts, reporting $7.93 billion in revenue (3.2% above consensus) and adjusted EPS of $1.86 (beating estimates by $0.03). Despite these beats, the stock declined—a classic “sell the news” reaction. Attention quickly shifted to management’s guidance and shrinking margins, which failed to satisfy the market’s elevated hopes.

The main disappointment was the outlook for 2026, with projected EPS at $8.65—about 1% below analyst expectations. More troubling was the operating margin, which dropped to 25% from 32.5% a year earlier, indicating unexpected cost pressures or changes in business mix. While the earnings beat was real, the forward guidance introduced new concerns about profitability.

To reassure shareholders, Gilead increased its quarterly dividend to $0.82, bringing the annual payout to $3.28 and yielding about 2.3%. This move signals confidence in the company’s cash flow, even as it invests heavily in oncology. It’s a way to reward loyal investors while the market weighs the risks of the new growth strategy.

The real divide lies in long-term projections. While consensus estimates for 2027 EPS stand at $7.95, some analysts, such as those at Zacks, foresee a much higher figure of $9.54. This gap between current consensus and more optimistic forecasts is at the heart of the investment debate. The latest earnings did not bridge this divide, instead highlighting the tension between short-term margin pressures and the long-term growth story that’s already reflected in the stock price.

GILD Stock Snapshot

• Ticker: GILD
• Company: Gilead Sciences
• Price: 134.250
• Change: -2.630 (-1.92%)
• Exchange: NASDAQ
• Status: Closed

Growth Concentration: New Bets vs. Established Strength

The market’s optimism is built on a delicate shift away from Gilead’s traditional HIV focus, but the company still faces significant concentration risk. The established HIV business continues to generate steady returns, while the anticipated new growth engines are not yet fully operational.

Biktarvy remains the cornerstone, now holding over 52% of the U.S. market. However, even this dominant product is expected to grow HIV sales by just 6% in 2026—a modest pace for a company priced for rapid expansion. The market is paying a premium for a growth story, but the guidance for its mainstay product remains conservative.

The future growth narrative depends on two largely untested areas: oncology and liver disease. The oncology strategy hinges on the $7.8 billion Arcellx acquisition and its CAR-T therapy, anito-cel, for multiple myeloma. The FDA’s decision on anito-cel, expected December 23, will either validate or undermine the entire oncology-driven re-rating. As of now, this therapy has yet to make a significant impact on revenue, meaning the market is pricing in potential that hasn’t materialized.

Liver disease is the other focal point, with Yeztugo showing early momentum. Management projects 2026 revenue for Yeztugo at $800 million, up sharply from $150 million in 2025. While this is a notable increase, it remains a small fraction of Gilead’s overall business. Despite talk of a diversified earnings base, the reality is that new products are not yet making a substantial contribution to the company’s bottom line.

This situation creates a clear mismatch between expectations and current performance. The stock is valued for a turnaround that has yet to be realized, with the Arcellx deal serving as the pivotal factor. Approval of anito-cel would accelerate oncology revenue and justify the premium, but any setback could unravel the growth narrative and leave Gilead reliant on its slow-growing HIV business. The current valuation is a high-risk wager on a catalyst that remains uncertain.

Valuation and Upcoming Catalysts: What’s Next?

Recent trading activity reflects the market’s uncertainty about Gilead’s growth prospects. Shares have climbed 19.13% over the past 120 days, but have dropped nearly 10% in the last month. This volatility highlights the ongoing tug-of-war between optimism and skepticism. While the stock previously surged on hopes of a turnaround, it now faces scrutiny as investors look for concrete results. At around $134, the share price is well below its 52-week high, suggesting that earlier enthusiasm is being tempered.

Despite this, some analysts remain bullish. Firms like Morgan Stanley and Mizuho continue to set ambitious targets, with Mizuho’s $170 price target implying significant upside. Their optimism is rooted in the Arcellx deal and the company’s expansion into new therapeutic areas. However, the recent pullback suggests that the broader market is waiting for tangible proof—specifically, the FDA’s decision on anito-cel in December.

This upcoming FDA ruling is the key catalyst. A favorable outcome would validate the Arcellx acquisition, accelerate oncology revenue, and help close the gap between current financials and the growth narrative. On the other hand, a negative decision could prompt a sharp downward revision in guidance, potentially sending the stock back toward the low $90s, especially if HIV growth also slows or the oncology strategy falters.

At present, Gilead trades at a forward P/E of 25.4—a premium valuation for a company with tepid sales growth and declining returns. This premium is entirely contingent on the success of its oncology pivot. The market is willing to pay for future potential, but any delay or disappointment could lead to swift punishment. The stakes are clear: the next catalyst is imminent, and the risk/reward equation hinges on its outcome.